OSX 200Alternative Names: OSX200
Latest Information Update: 19 Jul 2016
At a glance
- Originator Ossianix
- Mechanism of Action Myostatin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Duchenne muscular dystrophy
Most Recent Events
- 19 Jul 2016 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
- 19 Jul 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route)